MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria®/Seattle Children’s PfSPZ-LARC2 Vaccine: finalist in Vaccine Industry Excellence (VIE) awards for Best Prophylactic Vaccine Award
Sanaria®/Seattle Children's PfSPZ-LARC2 Vaccine: finalist in Vaccine Industry Excellence (VIE) awards for Best Prophylactic Vaccine Award!
Sanaria is a finalist in Vaccine Industry Excellence (VIE) awards for Best Logistics Technology & Cold Chain Delivery Award
Sanaria is a finalist in Vaccine Industry Excellence (VIE) awards for Best Logistics Technology & Cold Chain Delivery Award!
Employee of the Month: Mei-Chun Chen
The Sanaria employee of the month for February 2024 is Mei-Chun Chen. Mei is a member of the clinical team at Sanaria and was nominated for employee of the month in recognition of her superb work supporting the Indonesian soldier trial of PfSPZ Vaccine and PfSPZ-CVac.
Sanaria Inc. Receives Major Funding for Malaria (PfSPZ) Repository
Sanaria receives $1.5M from the Gates Foundation to make PfSPZ Challenge more accessible for future controlled human malaria infections (CHMIs) in the form of a repository.
Dr. Hoffman Discusses Sanaria’s Clinical Trials in Africa
An article discussing running clinical trials in Africa features Sanaria's CEO, Dr. Stephen Hoffman.
Sanaria and Collaborators Publish Major Review of PfSPZ Vaccines
The journal Expert Review of Vaccines just published a major, open-access review of the PfSPZ Vaccines co-authored by Sanaria’s staff and 21 collaborators from 25 institutions in the US, Europe, and Africa. The 24,000 word manuscript describes the origins, development, current status and future of Sanaria’s various vaccine platforms, emphasizing the unparalleled safety and protective efficacy of PfSPZ vaccines, innovations that have propelled progress, the critical role played by our collaborators, and the promise of PfSPZ vaccines to reduce the burden of malaria in travelers and residents of malaria-endemic areas across the world.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.